Clinical Study Results
Research Sponsor: MedImmune
Drug Studied: MEDI4736 with tremelimumab
Study Title: A study to learn about the safety of MEDI4736 with tremelimumab in
participants with advanced non-small cell lung cancer, also called NSCLC
Thank you!
Thank you for taking part in the clinical study for the study drugs MEDI4736 and tremelimumab.
MedImmune sponsored this study and believes it is important to share the results. An
independent non-profit organization called CISCRP helped prepare this summary of the study
results for you.
If you participated in the study and have questions about the results, please speak with the study
doctor or staff at your study site.
1